Improved effectiveness in the management of cardiovascular risk among type 2 diabetic patients in primary health care;Mejora de la efectividad en el manejo del riesgo cardiovascular de pacientes diabéticos tipo 2 en atención primaria

Atencion Primaria

Volumn 41, Issue 5, 2009, Pages 240-245

  Hormigo Pozo, Antonio ^a   Viciana López, María Ángeles ^a   Gómez Jiménez, Leonor ^a   Gallego Parrilla, María Dolores ^b   Orellana Lozano, Javier ^b   Morales Asencio, José Miguel ^c  

^a Centro de Salud Puerta Blanca   (Spain)

^b Medicina de Familia   (Spain)

^c Unidad de Efectividad e Investigación   (Spain)

Author keywords

Cardiovascular risk; Clinical guidelines; Effectiveness improvement; TypeIIdiabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GENERAL PRACTITIONER; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RISK ASSESSMENT; SPAIN;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 67349258915     PISSN: 02126567     EISSN: 15781275     Source Type: Journal    
DOI: 10.1016/j.aprim.2008.09.006     Document Type: Article

References (21)

1. J. Redón Control de la hipertensión arterial basado en la automedición ambulatoria de la presión arterial: Estudio APACHE Med Clin (Barc) 120 2003 728 733 (Pubitemid 36763874)
2. Estudio DISEHTAC II: diagnóstico y seguimiento de la hipertensión arterial en Cataluña. Comparación con los datos de 1996. Aten Primaria. 2005;35:7-11.
3. L.A. Álvarez-Sala, C. Suárez, T. Mantilla, J. Franch, L.M. Ruilope, and J.R. Banegas Estudio PREVENCAT: control del riesgo cardiovascular en atención primaria Med Clin (Barc) 124 2005 406 410 (Pubitemid 40562561)
4. EUROASPIRE II Group Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Eur Heart J 22 2001 554 572 (Pubitemid 32625245)
5. A.M. Audet, S. Greenfield, and M. Field Medical practice guidelines: current activities and future directions Ann Intern Med 30 1990 709 714 (Pubitemid 20363644)
6. K.N. Lohr, and M.J. Field A provisional instrument for assessing clinical practice guidelines M.J. Field K.N. Lohr Guidelines for clinical practice. From development to use 1992 National Academy Press Washington
7. F. Campbell, H.O. Dickinson, J.V.F. Cook, F.R. Beyer, M. Eccles, and J.M. Mason Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall BMC Health Serv Res 6 2006 47 (Pubitemid 43869498)
8. P.J. Greco, and J.M. Eisenberg Changing physicians' practices N Engl J Med 329 1993 1271 1274 (Pubitemid 23306334)
9. The Cochrane Review Group on Effective Practice Organisation of Care (EPOC) Getting evidence into practice Eff Health Care 5 1999 1 16
10. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technology Assessment. 2004;8 doi:10.1016/j.aprim.2008.09. 006. (Pubitemid 38279464)
11. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hipertensión J Hypertens 21 2003 1011 1053 (Pubitemid 36667855)
12. A.V. Chobaniam, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo and the National High Blood Pressure Education Program Coordinating Committee JAMA 289 2003 2560 2572
13. National Institutes of Health. National Heart, Lung, and Blood Institute. National Cholesterol Education Program. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002.
14. Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC) Adaptación española de la Guía Europea de Prevención Cardiovascular Rev Esp Salud Pública 78 2004 435 438 (Pubitemid 39006383)
15. Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios. Rev Esp Cardiol. 2004;57:963-80.
16. J.P. Casas, W. Chua, S. Loukogeorgakis, P. Vallance, L. Smeeth, and A.D. Hingorani Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet 366 2005 2026 2033 (Pubitemid 41773378)
17. E.J. Lewis, and J.B. Lewis ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner? J Am Soc Nephrol 15 2004 1358 1360 (Pubitemid 38526020)
18. B.M. Brenner, M.E. Cooper, D. De Zeeuw, W.F. Keane, W.E. Mitch, and H.H. Parving Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
19. H.H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, and P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
20. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, and J.B. Lewis Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
21. H.A. Barnett, C.B. Stephen, P. Bouter, B. Karlberg, S. Madsbad, and J. Jervell Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy N Engl J Med 351 2004 1952 1961 (Pubitemid 39447136)